GlassScriptPhysician profile
James Grotta
NPI 1861422404
$31,175.93
in general payments reported to CMS, 2019-2025
17 companies · $95.96 in 2025
The $95.96 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $12K · 2021: $11.17 · 2022: $5,026 · 2023: $1,343 · 2024: $139 · 2025: $95.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,170 · Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,170.18 |
| Food and Beverage | $408.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Haemonetics Corporation | $13,359.73 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,134.83 | 2019 | |
| Astrazeneca Uk Limited | $3,998.86 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $3,233.17 | 2020-2021 | |
| Samsung Hme America, INC. | $2,709.61 | 2020-2025 | |
| Valeritas, INC. | $175.52 | 2019 | |
| Amgen INC. | $158.06 | 2019-2023 | Repatha, Otezla |
| Grifols USA, LLC | $124.14 | 2024 | Gamunex-C |
| Janssen Pharmaceuticals, INC | $70.96 | 2019 | |
| Astrazeneca Ab | $47.00 | 2020 | |
| Sanofi Pasteur INC. | $36.02 | 2023 | |
| Tandem Diabetes Care, INC. | $29.50 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Portola Pharmaceuticals, LLC | $28.55 | 2020 | |
| Insulet Corporation | $27.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.03 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $15.25 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Grotta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.